Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
11 déc. 2022 10h00 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster...
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
04 nov. 2021 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief...
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
01 sept. 2021 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas...
Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update
12 août 2021 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
- Entered into a licensing agreement with two leading oncology research and treatment centers for use of CaspaCIDe® safety switch technology - - Enrollment continuing in Phase 1/2 dose-escalation...
Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch
28 juin 2021 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has...
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
17 mai 2021 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity
04 mars 2021 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the...
Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson
11 déc. 2019 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The...